{"title":"更正“Oroxylin A通过抑制M1巨噬细胞极化直接靶向p62 （sequestosome 1）减轻牛皮癣样皮肤炎症”。","authors":"","doi":"10.1111/bph.70149","DOIUrl":null,"url":null,"abstract":"<p>\n <span>Ma, Y</span>, <span>Liu, Y</span>, <span>Zhong, Y</span>, <span>Li, X</span>, <span>Xu, Y</span>, <span>Chen, L</span>, <span>Gong, L</span>, <span>Huang, H</span>, <span>Chen, X</span>, <span>He, Y</span>, <span>Qiang, L</span>. <span>Oroxylin A attenuates psoriasiform skin inflammation by direct targeting p62 (sequestosome 1) via suppressing M1 macrophage polarization</span>. <i>Br J Pharmacol.</i> <span>2024 Dec</span>; <span>181</span>(<span>24</span>): <span>5110</span>–<span>5132</span>. https://doi.org/10.1111/bph.17349. Epub 2024 Sep 23. PMID: 39313956.</p><p>In last line of the “funding information” section, the funding number “AD220359310” was incorrect. This should be corrected to “AD22035191”. Also, the location of this funding number “AD22035191” should be swapped with the first funding number, “2022KY0513”.</p><p>Therefore, the entire content of the funding information section should ultimately be revised as follows: ‘Special Fund for Talents of Guangxi, Grant/Award Number: AD22035191; Natural Science Foundation of Jiangsu Province, Grant/Award Numbers: BK20210419, BK20211578; National Natural Science Foundation of China, Grant/Award Numbers: 81974425, 82002907, 82360718; Basic Ability Enhancement Program for Young and Middle-aged Teachers of Guilin Medical University, Grant/Award Number: 2022KY0513’.</p><p>The entire content of the second sentence in the last paragraph of the Methods section (2.2 Cell culture and primary cell isolation) should ultimately be revised as follows: “All the protocols and procedures were ethically approved and confirmed by 2017-KY-022 from Institute of Dermatology, Chinese Academy of Medical Science, Peking Union Medical College.”</p><p>We apologize for this error.</p>","PeriodicalId":9262,"journal":{"name":"British Journal of Pharmacology","volume":"182 17","pages":""},"PeriodicalIF":7.7000,"publicationDate":"2025-07-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/bph.70149","citationCount":"0","resultStr":"{\"title\":\"Correction to “Oroxylin A attenuates psoriasiform skin inflammation by direct targeting p62 (sequestosome 1) via suppressing M1 macrophage polarization”\",\"authors\":\"\",\"doi\":\"10.1111/bph.70149\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p>\\n <span>Ma, Y</span>, <span>Liu, Y</span>, <span>Zhong, Y</span>, <span>Li, X</span>, <span>Xu, Y</span>, <span>Chen, L</span>, <span>Gong, L</span>, <span>Huang, H</span>, <span>Chen, X</span>, <span>He, Y</span>, <span>Qiang, L</span>. <span>Oroxylin A attenuates psoriasiform skin inflammation by direct targeting p62 (sequestosome 1) via suppressing M1 macrophage polarization</span>. <i>Br J Pharmacol.</i> <span>2024 Dec</span>; <span>181</span>(<span>24</span>): <span>5110</span>–<span>5132</span>. https://doi.org/10.1111/bph.17349. Epub 2024 Sep 23. PMID: 39313956.</p><p>In last line of the “funding information” section, the funding number “AD220359310” was incorrect. This should be corrected to “AD22035191”. Also, the location of this funding number “AD22035191” should be swapped with the first funding number, “2022KY0513”.</p><p>Therefore, the entire content of the funding information section should ultimately be revised as follows: ‘Special Fund for Talents of Guangxi, Grant/Award Number: AD22035191; Natural Science Foundation of Jiangsu Province, Grant/Award Numbers: BK20210419, BK20211578; National Natural Science Foundation of China, Grant/Award Numbers: 81974425, 82002907, 82360718; Basic Ability Enhancement Program for Young and Middle-aged Teachers of Guilin Medical University, Grant/Award Number: 2022KY0513’.</p><p>The entire content of the second sentence in the last paragraph of the Methods section (2.2 Cell culture and primary cell isolation) should ultimately be revised as follows: “All the protocols and procedures were ethically approved and confirmed by 2017-KY-022 from Institute of Dermatology, Chinese Academy of Medical Science, Peking Union Medical College.”</p><p>We apologize for this error.</p>\",\"PeriodicalId\":9262,\"journal\":{\"name\":\"British Journal of Pharmacology\",\"volume\":\"182 17\",\"pages\":\"\"},\"PeriodicalIF\":7.7000,\"publicationDate\":\"2025-07-13\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://onlinelibrary.wiley.com/doi/epdf/10.1111/bph.70149\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"British Journal of Pharmacology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://bpspubs.onlinelibrary.wiley.com/doi/10.1111/bph.70149\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"PHARMACOLOGY & PHARMACY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"British Journal of Pharmacology","FirstCategoryId":"3","ListUrlMain":"https://bpspubs.onlinelibrary.wiley.com/doi/10.1111/bph.70149","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0
摘要
Ma， Y, Liu， Y, Zhong， Y, Li， X, Xu， Y, Chen， L, Gong， L, Huang， H, Chen， X, He， Y, Qiang， L. Oroxylin A通过抑制M1巨噬细胞极化直接靶向p62 （sequestosome 1）减轻银屑病样皮肤炎症。中国生物医学工程杂志。2009；181(24): 5110 - 5132。https://doi.org/10.1111/bph.17349。2024年9月23日。PMID: 39313956。在“资助信息”部分的最后一行，资助号“AD220359310”不正确。这应该更正为“AD22035191”。此外，该资助号“AD22035191”的位置应与第一个资助号“2022KY0513”交换。因此，资助信息部分的整体内容最终应修改如下：“广西人才专项资金，资助/奖励号：AD22035191；江苏省自然科学基金项目，资助/奖励号：BK20210419， BK20211578；国家自然科学基金项目，资助/奖励号：81974425,82002907,82360718；桂林医科大学中青年教师基本能力提升项目，资助/奖励号：2022KY0513。方法部分最后一段第二句的全部内容（2.2细胞培养和原代细胞分离）最终应修改为：“所有的方案和程序均经北京协和医学院中国医学科学院皮肤病学研究所2017- key -022的伦理批准和确认。”我们为这个错误道歉。
Correction to “Oroxylin A attenuates psoriasiform skin inflammation by direct targeting p62 (sequestosome 1) via suppressing M1 macrophage polarization”
Ma, Y, Liu, Y, Zhong, Y, Li, X, Xu, Y, Chen, L, Gong, L, Huang, H, Chen, X, He, Y, Qiang, L. Oroxylin A attenuates psoriasiform skin inflammation by direct targeting p62 (sequestosome 1) via suppressing M1 macrophage polarization. Br J Pharmacol.2024 Dec; 181(24): 5110–5132. https://doi.org/10.1111/bph.17349. Epub 2024 Sep 23. PMID: 39313956.
In last line of the “funding information” section, the funding number “AD220359310” was incorrect. This should be corrected to “AD22035191”. Also, the location of this funding number “AD22035191” should be swapped with the first funding number, “2022KY0513”.
Therefore, the entire content of the funding information section should ultimately be revised as follows: ‘Special Fund for Talents of Guangxi, Grant/Award Number: AD22035191; Natural Science Foundation of Jiangsu Province, Grant/Award Numbers: BK20210419, BK20211578; National Natural Science Foundation of China, Grant/Award Numbers: 81974425, 82002907, 82360718; Basic Ability Enhancement Program for Young and Middle-aged Teachers of Guilin Medical University, Grant/Award Number: 2022KY0513’.
The entire content of the second sentence in the last paragraph of the Methods section (2.2 Cell culture and primary cell isolation) should ultimately be revised as follows: “All the protocols and procedures were ethically approved and confirmed by 2017-KY-022 from Institute of Dermatology, Chinese Academy of Medical Science, Peking Union Medical College.”
期刊介绍：
The British Journal of Pharmacology (BJP) is a biomedical science journal offering comprehensive international coverage of experimental and translational pharmacology. It publishes original research, authoritative reviews, mini reviews, systematic reviews, meta-analyses, databases, letters to the Editor, and commentaries.
Review articles, databases, systematic reviews, and meta-analyses are typically commissioned, but unsolicited contributions are also considered, either as standalone papers or part of themed issues.
In addition to basic science research, BJP features translational pharmacology research, including proof-of-concept and early mechanistic studies in humans. While it generally does not publish first-in-man phase I studies or phase IIb, III, or IV studies, exceptions may be made under certain circumstances, particularly if results are combined with preclinical studies.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
